Friday, July 10, 2026

Drug profile · INN

teriparatide acetate

teriparatide acetate (PARATHAR) is a parathyroid hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — teriparatide acetate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

teriparatide acetate (PARATHAR) is a parathyroid hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN teriparatide acetate
Brand PARATHAR
Mechanism Parathyroid hormone receptor agonist
Target Parathyroid hormone/parathyroid hormone-related peptide receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Parathyroid hormone receptor agonist

Primary target: Parathyroid hormone/parathyroid hormone-related peptide receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. parathyroid hormone Systemic hormonal preparations (H05)
  2. teriparatide Systemic hormonal preparations (H05)
  3. abaloparatide Systemic hormonal preparations (H05)
  4. palopegteriparatide Systemic hormonal preparations (H05)
  5. parathyroid hormone (rdna) Systemic hormonal preparations (H05)

Frequently asked questions

What is teriparatide acetate?

teriparatide acetate (PARATHAR) is a parathyroid hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for teriparatide acetate?

PARATHAR is a marketed brand name for teriparatide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of teriparatide acetate?

teriparatide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.